

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Illinois Insurance Code is amended by  
5 changing Section 356u as follows:

6 (215 ILCS 5/356u)

7 Sec. 356u. Pap tests and prostate cancer screenings.

8 (a) A group policy of accident and health insurance that  
9 provides coverage for hospital or medical treatment or  
10 services for illness on an expense-incurred basis and is  
11 amended, delivered, issued, or renewed after January 1, 2024  
12 shall provide coverage, without imposing a deductible,  
13 coinsurance, copayment, or any other cost-sharing requirement,  
14 for all of the following:

15 (1) An annual cervical smear or Pap smear test for all  
16 ~~female~~ insureds.

17 (2) An annual prostate cancer screening for ~~male~~  
18 insureds upon the recommendation of a physician licensed  
19 to practice medicine in all its branches for:

20 (A) asymptomatic individuals ~~men~~ age 50 and over;

21 (B) African-American individuals ~~men~~ age 40 and  
22 over; and

23 (C) individuals ~~men~~ age 40 and over with a family

1 history of or genetic predisposition to prostate  
2 cancer.

3 (3) Surveillance tests for ovarian cancer for ~~female~~  
4 insureds who are at risk for ovarian cancer.

5 (b) This Section shall not apply to agreements, contracts,  
6 or policies that provide coverage for a specified disease or  
7 other limited benefit coverage.

8 (c) This Section does not apply to coverage of prostate  
9 cancer screenings to the extent such coverage would disqualify  
10 a high-deductible health plan from eligibility for a health  
11 savings account pursuant to Section 223 of the Internal  
12 Revenue Code.

13 (d) For the purposes of this Section:

14 "At risk for ovarian cancer" means:

15 (1) having a family history (i) with one or more  
16 first-degree relatives with ovarian cancer, (ii) of  
17 clusters of ~~women~~ relatives with breast cancer, or (iii)  
18 of nonpolyposis colorectal cancer; or

19 (2) testing positive for BRCA1 or BRCA2 mutations.

20 "Prostate cancer screening" means medically viable methods  
21 for the detection and diagnosis of prostate cancer, including  
22 a digital rectal exam and the prostate-specific antigen test  
23 and associated laboratory work. "Prostate cancer screening"  
24 includes medically necessary subsequent follow-up testing as  
25 directed by a health care provider, including, but not limited  
26 to:

- 1           (1) urinary analysis;
- 2           (2) serum biomarkers; and
- 3           (3) medical imaging, including, but not limited to,
- 4           magnetic resonance imaging.

5           "Surveillance tests for ovarian cancer" means annual

6           screening using (i) CA-125 serum tumor marker testing, (ii)

7           transvaginal ultrasound, (iii) pelvic examination.

8           (Source: P.A. 102-1073, eff. 1-1-23.)

9           Section 99. Effective date. This Act takes effect January

10          1, 2025.